Briggs Morrison - 17 Dec 2021 Form 4 Insider Report for Syndax Pharmaceuticals Inc (SNDX)

Role
Chief Executive Officer, Director
Signature
/s/ Michael A. Metzger, Attorney-in-fact
Issuer symbol
SNDX
Transactions as of
17 Dec 2021
Net transactions value
-$319,920
Form type
4
Filing time
20 Dec 2021, 17:44:51 UTC
Previous filing
21 Sep 2021
Next filing
19 Jan 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SNDX Common Stock Options Exercise $383,200 +35,156 +73% $10.90 83,492 17 Dec 2021 Direct
transaction SNDX Common Stock Sale $703,120 -35,156 -42% $20.00 48,336 17 Dec 2021 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SNDX Stock Options (Right to buy) Options Exercise $0 -35,156 -100% $0.000000* 0 17 Dec 2021 Common Stock 35,156 $10.90 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person. Following the sales reported in this Form 4, the Reporting Person has a total of 1,305,602 options to purchase shares of common stock that are vested and immediately exercisable and a total of 339,083 options to purchase shares of common stock that have not yet vested.
F2 This option is fully vested.